Cabozantinib Plus Nivolumab and Ipilimumab Results in Longer PFS in Previously Untreated, Advanced RCC with Intermediate or Poor Prognostic Risk
Findings from the COSMIC-313 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1586 results
EMA Recommends Granting a Conditional Marketing Authorisation for Glofitamab
It is intended for the treatment of adult patients with relapsed or refractory DLBCL after two or more lines of systemic treatment
POT1 Mutations Associated with Long Telomere Length Confer a Predisposition to a Familial Clonal Haematopoiesis Syndrome
An inherited cancer-predisposition mechanism distinct from that of mutations affecting tumour-suppressor proteins and oncoproteins
Multi-Organ Genomic Analysis of Resistant Cutaneous Melanoma Provides Insights for Potential Improvement of Treatment Strategies
Findings from genomic analysis in a rapid autopsy cohort study
Long-Term Benefit of Sotorasib in Patients with Pretreated KRASG12C-Mutated NSCLC
Findings from 2-year analysis of CodeBreaK 100 study
A Propensity Score Matched Study Supports the Use of Allogeneic HSCT in Advanced-Stage, High-Risk Cutaneous T-Cell Lymphomas
Findings from the CUTALLO study
EMA Recommends Extension of Indications for Nivolumab and Ipilimumab
Extended indication concerns the treatment of melanoma in adolescents 12 years of age and older
Favourable Benefit-Risk Profile of Trastuzumab Deruxtecan in Patients with HER2-positive MBC Who were Previously Treated with Trastuzumab Emtansine
Findings from the DESTINY-Breast02 study
A Combination of Trifluridine-Tipiracil Plus Bevacizumab Results in Longer Overall Survival Among Patients with Refractory mCRC
Findings from the SUNLIGHT study
Temporary Interruption of Adjuvant Endocrine Treatment to Attempt Pregnancy Does Not Increase Short-Term Risk for Worsening Breast Cancer Outcomes
Findings from the POSITIVE study
EMA Recommends Granting a Conditional Marketing Authorisation for Pirtobrutinib
It is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma who have been previously treated with a Bruton’s tyrosine kinase inhibitor
Initial Results of the CanScreen5, an Authentic Data Repository for Cancer Screening Globally
Substantial heterogeneity observed in cancer screening programme organisation and performance